Serum IL-17, IL-23, and TGF-Î²Levels in Type 1 an Healthy Controls

BioMed Research International

2014, 1-7

DOI: 10.1155/2014/718946

Citation Report

#	Article	IF	Citations
1	ILâ€17 cytokines in bone healing of diabetic Charcot arthropathy patients: a prospective 2 year followâ€up study. Journal of Foot and Ankle Research, 2015, 8, 39.	1.9	11
2	Th17 involvement in nonalcoholic fatty liver disease progression to non-alcoholic steatohepatitis. World Journal of Gastroenterology, 2016, 22, 9096.	3.3	39
3	Changes of Regulatory T Cells and of Proinflammatory and Immunosuppressive Cytokines in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. Journal of Diabetes Research, 2016, 2016, 1-19.	2.3	86
4	Interleukin-17AGene Variability in Patients with Type 1 Diabetes Mellitus and Chronic Periodontitis: Its Correlation with IL-17 Levels and the Occurrence of Periodontopathic Bacteria. Mediators of Inflammation, 2016, 2016, 1-9.	3.0	31
5	Novel inflammatory markers for incident pre-diabetes and type 2 diabetes: the Rotterdam Study. European Journal of Epidemiology, 2017, 32, 217-226.	5.7	48
6	Comparative and correlative assessments of cytokine, complement and antibody patterns in paediatric type 1 diabetes. Clinical and Experimental Immunology, 2017, 190, 110-121.	2.6	16
7	Interleukinâ€17 as a factor linking the pathogenesis of psoriasis with metabolic disorders. International Journal of Dermatology, 2017, 56, 260-268.	1.0	30
8	Impact of Tâ€cellâ€specific Smad4 deficiency on the development of autoimmune diabetes in NOD mice. Immunology and Cell Biology, 2017, 95, 287-296.	2.3	8
9	The potential pathogenic role of IL-17/Th17 cells in both type 1 and type 2 diabetes mellitus. Biomedicine and Pharmacotherapy, 2018, 101, 287-292.	5.6	141
10	Levels of Interleukin 27 and Interleukin 35 in the Serum and Vitreous of Patients with Proliferative Diabetic Retinopathy. Ocular Immunology and Inflammation, 2018, 26, 273-279.	1.8	13
11	TLR-induced secretion of novel cytokine IL-27 is defective in newly diagnosed type-2 diabetic subjects. Cytokine, 2018, 104, 65-71.	3.2	7
12	Targeting inflammation in diabetic nephropathy: a tale of hope. Expert Opinion on Investigational Drugs, 2018, 27, 917-930.	4.1	133
13	Th17 and Treg lymphocytes in obesity and Type 2 diabetic patients. Clinical Immunology, 2018, 197, 77-85.	3.2	63
14	Gut Microbiota-Stimulated Innate Lymphoid Cells Support Î²-Defensin 14 Expression in Pancreatic Endocrine Cells, Preventing Autoimmune Diabetes. Cell Metabolism, 2018, 28, 557-572.e6.	16.2	84
15	The ratios of pro-inflammatory to anti-inflammatory cytokines in the serum of chronic periodontitis patients with and without type 2 diabetes and/or smoking habit. Clinical Oral Investigations, 2019, 23, 641-650.	3.0	42
16	The Differential Roles of T Cells in Non-alcoholic Fatty Liver Disease and Obesity. Frontiers in Immunology, 2019, 10, 82.	4.8	157
17	Level of inflammatory cytokines tumour necrosis factor ï¡, interleukins 12, 23 and 17 in patients with psoriasis in the context of metabolic syndrome. Postepy Dermatologii I Alergologii, 2019, 36, 70-75.	0.9	7
18	The co-activator-associated arginine methyltransferase 1 (CARM1) gene is overexpressed in type 2 diabetes. Endocrine, 2019, 63, 284-292.	2.3	17

#	Article	IF	Citations
19	Effects of plant and animal high protein diets on immune-inflammatory biomarkers: A 6-week intervention trial. Clinical Nutrition, 2020, 39, 862-869.	5.0	28
20	Microbiota and Diabetes Mellitus: Role of Lipid Mediators. Nutrients, 2020, 12, 3039.	4.1	52
21	Decreased serum levels of interleukinâ€17, interleukinâ€23, <scp>TGF</scp> âÎ² in pemphigus vulgaris patients, and their association with disease phase. Dermatologic Therapy, 2020, 33, e14071.	1.7	5
22	Confirmation and Identification of Biomarkers Implicating Environmental Triggers in the Pathogenesis of Type 1 Diabetes. Frontiers in Immunology, 2020, 11, 1922.	4.8	9
23	Evaluation of Interleukin-23 and JAKs/STATs/SOCSs/ROR-Î³t Expression in Type 2 Diabetes Mellitus Patients Treated With or Without Sitagliptin. Journal of Interferon and Cytokine Research, 2020, 40, 515-523.	1.2	6
24	Salivary and serum interleukin-17A and interleukin-18 levels in patients with type 2 diabetes mellitus with and without periodontitis. PLoS ONE, 2020, 15, e0228921.	2.5	15
25	Tildrakizumab efficacy, drug survival, and safety are comparable in patients with psoriasis with and without metabolic syndrome: Long-term results from 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2). Journal of the American Academy of Dermatology, 2021, 84, 398-407.	1.2	11
26	Immunopathology of Type 1 Diabetes and Immunomodulatory Effects of Stem Cells: A Narrative Review of the Literature. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2021, 21, .	1.2	2
27	Randomized research on the mechanism of local oxygen therapy promoting wound healing of diabetic foot based on RNA-seq technology. Annals of Palliative Medicine, 2021, 10, 973-983.	1.2	2
28	Vitamin D status, proinflammatory cytokines and bone mineral density in Mexican people with multiple sclerosis. Multiple Sclerosis and Related Disorders, 2021, 56, 103265.	2.0	2
29	Stat3-mTOR signaling mediates the stimulation of GLP-1 production induced by IL-27. Journal of Molecular Endocrinology, 2019, 63, 215-226.	2.5	2
30	An Immunologic Approach to the Pathogenesis of Type 1 Diabetes. Global Journal of Pathology and Microbiology, 2015, 2, 47-52.	0.0	0
31	Crosstalk Between Gut Microbiota, Innate Lymphoid Cells and Endocrine Cells in the Pancreas Regulates Autoimmune Diabetes. SSRN Electronic Journal, 0, , .	0.4	0
32	Healthy Adult LDL-C Bears Reverse Association with Serum IL-17A Levels. Current Chemical Genomics and Translational Medicine, 2018, 12, 1-8.	4.3	2
33	The role of IL-17 in the pathogenesis of type 1 and type 2 diabetes mellitus in humans. MÃ¬Å¾narodnij EndokrinologÃ¬Änij Å½urnal, 2018, 14, 514-521.	0.4	3
34	The Level and Role of Interleukin-17 in Patients of Type 2 Diabetes Mellitus with and without Complications. Journal of Diabetes Mellitus, 2019, 09, 176-185.	0.3	6
35	Cytokines in the blood of patients with type 2 diabetes mellitus depending on the level of overweight/obesity (literature review and own data). MÃ¬Å¾narodnij EndokrinologÃ¬Änij Å½urnal, 2021, 17, 534-551.	0.4	4
36	Immunological and hematological estimation of matrix metalloproteinase-9 (MMP9) level in a serum of female infested through trichomonas vaginalis. AIP Conference Proceedings, 2022, , .	0.4	0

#	Article	IF	Citations
37	Changes of Th17 cells, regulatory T cells, Treg/Th17, IL-17 and IL-10 in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Endocrine, 2022, 76, 263-272.	2.3	9
38	IL-17A in diabetic kidney disease: protection or damage. International Immunopharmacology, 2022, 108, 108707.	3.8	3
42	Visfatin Protects Rat Pancreatic Î²-cells against IFN-Î³-Induced Apoptosis through AMPK and ERK1/2 Signaling Pathways. Biomedical and Environmental Sciences, 2015, 28, 169-77.	0.2	13
43	PCSK9 Contributes to the Cholesterol, Glucose, and Insulin2 Homeostasis in Seminiferous Tubules and Maintenance of Immunotolerance in Testis. Frontiers in Cell and Developmental Biology, 2022, 10, 889972.	3.7	2
44	Diyabetik Periferik PolinÃ¶ropatili Hastalarda Ä°nterlÃ¶kin-23R Gen Polimofizmleri. Konuralp Tip Dergisi, 2022, 14, 406-410.	0.3	0
45	Probiotics: Protecting Our Health from the Gut. Microorganisms, 2022, 10, 1428.	3.6	20
46	Variable frequencies of peripheral T-lymphocyte subsets in the diabetes spectrum from type 1 diabetes through latent autoimmune diabetes in adults (LADA) to type 2 diabetes. Frontiers in Immunology, 0, 13, .	4.8	7
47	Cytokine Profile in Patients With Maturity-onset Diabetes of the Young (MODY). In Vivo, 2022, 36, 2490-2504.	1.3	1
48	Intestinal Microbiomics in Physiological and Pathological Conditions. , 0, , .		1
49	Immunological mechanisms of increased susceptibility to COVID-19 disease and its severe course in patients with diabetes mellitus type 2 and obesity. Ukrainian Biochemical Journal, 2023, 95, 5-23.	0.5	1
50	Targeting IL-12 family cytokines: A potential strategy for type 1 and type 2 diabetes mellitus. Biomedicine and Pharmacotherapy, 2024, 170, 115958.	5.6	0